Identifying the ages when Alzheimer’s biomarkers sharply change

New research pinpoints the ages when Alzheimer’s-related brain changes accelerate, offering critical clues to when screening may be most effective.

Study: Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging. Image credit: Orawan Pattarawimonchai/Shutterstock.com

A recent study published in Alzheimer's and Dementia investigated the specific ages at which Alzheimer's disease biomarkers and cognitive measures experience significant slope changes, providing insight into the timing of early pathological processes across the aging spectrum.

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by gradual cognitive decline, beginning with subtle memory loss and advancing to impairments in orientation, reasoning, language, and daily functioning. As the disease progresses, neuropsychiatric symptoms and loss of independence become increasingly common.